Henry Schein, Inc. (HSIC) News
Filter HSIC News Items
HSIC News Results
|Loading, please wait...|
HSIC News Highlights
- HSIC's 30 day story count now stands at 46.
- Over the past 17 days, the trend for HSIC's stories per day has been choppy and unclear. It has oscillated between 3 and 13.
- BEAT, ABT and AGCO are the most mentioned tickers in articles about HSIC.
Latest HSIC News From Around the Web
Below are the latest news stories about Henry Schein Inc that investors may wish to consider to help them evaluate HSIC as an investment opportunity.
Nevro's (NVRO) worldwide revenues fall on a year-over-year basis in Q4 due to soft geographical performances.
Avanos Medical's (AVNS) fourth-quarter 2021 results gain from strength in the chronic care segment.
MELVILLE, N.Y., February 24, 2022--Henry Schein announces support for inaugural Women in DSO event, "Empower and Grow 2022."
Integra (IART) records strong recovery in order demand in Q4 on broad-based strength in Neurosurgery and sales from the company's new CereLink ICP monitoring.
Insulet's (PODD) fourth-quarter 2021 revenues improved year over year on a strong performance of Omnipod, both in U.S. and international markets.
Continued strong international performance and introduction of products drove NuVasive's (NUVA) revenues in the fourth quarter of 2021.
Robust performances by the Home Health and Hospice segments drove Amedisys' (AMED) fourth-quarter top line.
Cerner's (CERN) fourth-quarter results benefit from gains across four of its business units.
Despite the weak bottom-line performance, LHC Group's (LHCG) fourth-quarter results benefit from organic growth in home health admissions.
Abbott (ABT) registers strong growth in its more consumer-facing businesses like nutrition, established pharmaceuticals and diabetes care.